Minnie Sarwal, MD, PhD
Professor in Residence, Surgery, Division of MultiOrgan Transplantation, UCSF
Professor, Medicine, Pediatrics, UCSF
Medical Director (interim), Kidney-Pancreas Transplant Program, UCSF
Director, Precision Transplant Medicine, SarwalLab, UCSF
Co-Director, T32 Training Grant, Transplant Surgery, UCSF
Capstone Mentor, Masters in Translational Medicine, Berkeley/UCSF
Consulting Professor, Haas, University of California, Berkeley
Professor, Immunology, Peds, Surgery (1997-2012), Stanford University
Medical Director (2008-2012), Pediatric Kidney Transplant Program, Stanford University
Summary:
Minnie Sarwal has over 30 years of clinical experience and 25 years of research experience in translational immunogenetics, genomics, proteomics and informatics. She holds a PhD in Molecular Genetics from Cambridge University (Christ's College), under the mentorship of Nobel Laureate Sydney Brenner; a Diploma in Child Health from London, UK; Membership of the Royal College of Physicians and elected Fellow of the Royal College of Physicians, UK.
Dr. Sarwal has held the Professor of Surgery/Immunology/Peds and the Medical Director position in the Peds Kidney Transplant Program at Stanford University. She headed a personalized medicine initiative for Sutter Health and is currently Professor of Surgery at UCSF. In an international election, she was selected Councillor for the TTS in 2014, and in a university wide election voted in as Senator-at-large on the Faculty Senate for Stanford Medical School. She has been an Asian-American and Women's Mentor at Stanford University, has chaired sections for the AST/ASTS/TTS, and serves on NIH study sections.
Minnie has directed the Sarwal Lab since 1997 and manages high caliber clinical and scientific staff. She founded Organ-I, a company for personalization of transplant medicine, spun out of Stanford; recently acquired by Immucor.
Minnie has leadership skills in the development, delivery and evaluation of services in large medical centers in the USA and England, securing pharma and NIH funding and expanding clinical services in a competitive environment. She is a KOL in the field of renal and transplant medicine, genomics, proteomics and immunology. As PI for industry and NIH multicenter clinical trials, she leads trial design, execution, and human subject safety policies. As an enterpreneur, she has founded and sold a diagnostic company and is experienced in legal, fiscal, regulatory and reimbursement requirements for product development and commercialization.